AbbVie Seeks Approval of Risankizumab for Crohn Disease
The application is supported by data from two phase 3 induction studies (ADVANCE and MOTIVATE) and one phase 3 maintenance study (FORTIFY).
Colorectal And Other GI Cancers
Tislelizumab Under Review for Esophageal Squamous Cell Carcinoma
The application is supported by data from the phase 3 RATIONALE 302 trial.
Very High Antibiotic Use May Up Risk for Proximal Colon Cancer
Inverse association seen for antibiotic use and rectal cancer, which seems to be driven by women
Antihypertensives Linked to Reduced Mortality in Colorectal Cancer
Reductions in mortality seen in association with ACE inhibitors, beta-blockers, thiazide diuretics
Tibsovo Approved for IDH1-Mutated Cholangiocarcinoma
The approval was based on data from the double-blind, placebo-controlled ClarIDHy study.
Jemperli Gets Accelerated Approval for dMMR Recurrent or Advanced Solid Tumors
The accelerated approval was based on data from the phase 1 GARNET trial.
Popular Cancer-Related Social Media Posts Can Contain Misinformation
One-third of posts contain misinformation, of which most may be harmful
Multitarget Fecal Immunochemical Test Ups Diagnostic Accuracy
Cross-validated sensitivity improved with multitarget FIT compared with standard FIT test for advanced neoplasia and advanced adenoma
Keytruda Indication for Advanced Gastric Cancer Withdrawn
In September 2017, the FDA granted accelerated approval to Keytruda for recurrent locally advanced or metastatic gastric or GEJ adenocarcinoma.
FDA Panel Votes to Defer Decision on Retifanlimab for Anal Cancer
The BLA submission is supported by data from the phase 2 POD1UM-202 study, which evaluated retifanlimab in patients with locally advanced or metastatic SCAC who progressed after platinum-based chemotherapy.
